Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2.

Marchetti F, Sayle KL, Bentley J, Clegg W, Curtin NJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Harrington RW, Mesguiche V, Newell DR, Noble ME, Parsons RJ, Pratt DJ, Wang LZ, Hardcastle IR.

Org Biomol Chem. 2007 May 21;5(10):1577-85. Epub 2007 Apr 23.

PMID:
17571187
[PubMed - indexed for MEDLINE]
2.

Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.

Sayle KL, Bentley J, Boyle FT, Calvert AH, Cheng Y, Curtin NJ, Endicott JA, Golding BT, Hardcastle IR, Jewsbury P, Mesguiche V, Newell DR, Noble ME, Parsons RJ, Pratt DJ, Wang LZ, Griffin RJ.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3079-82.

PMID:
12941338
[PubMed - indexed for MEDLINE]
3.

Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors.

Marchetti F, Cano C, Curtin NJ, Golding BT, Griffin RJ, Haggerty K, Newell DR, Parsons RJ, Payne SL, Wang LZ, Hardcastle IR.

Org Biomol Chem. 2010 May 21;8(10):2397-407. doi: 10.1039/b925481a. Epub 2010 Mar 18.

PMID:
20448898
[PubMed - indexed for MEDLINE]
4.

Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates.

Wong C, Griffin RJ, Hardcastle IR, Northen JS, Wang LZ, Golding BT.

Org Biomol Chem. 2010 May 21;8(10):2457-64. doi: 10.1039/b922717b. Epub 2010 Mar 24.

PMID:
20448906
[PubMed - indexed for MEDLINE]
5.

4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.

Mesguiche V, Parsons RJ, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury P, Johnson LN, Newell DR, Noble ME, Wang LZ, Hardcastle IR.

Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.

PMID:
12482427
[PubMed - indexed for MEDLINE]
6.

3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.

Singh SK, Dessalew N, Bharatam PV.

Med Chem. 2007 Jan;3(1):75-84.

PMID:
17266627
[PubMed - indexed for MEDLINE]
7.

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.

Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding Q, Jiang N, Wang K, Goelzer P, Yin X, Smith MA, Higgins BX, Chen Y, Xiang Q, Moliterni J, Kaplan G, Graves B, Lovey A, Fotouhi N.

J Med Chem. 2006 Nov 2;49(22):6549-60.

PMID:
17064073
[PubMed - indexed for MEDLINE]
8.

Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.

Gibson AE, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, Tucker JA, Whitfield HJ.

J Med Chem. 2002 Aug 1;45(16):3381-93.

PMID:
12139449
[PubMed - indexed for MEDLINE]
9.

Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.

Ibrahim DA, Ismail NS.

Eur J Med Chem. 2011 Dec;46(12):5825-32. doi: 10.1016/j.ejmech.2011.09.041. Epub 2011 Oct 1.

PMID:
22000924
[PubMed - indexed for MEDLINE]
10.

Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.

Ahn YM, Vogeti L, Liu CJ, Santhapuram HK, White JM, Vasandani V, Mitscher LA, Lushington GH, Hanson PR, Powell DR, Himes RH, Roby KF, Ye Q, Georg GI.

Bioorg Med Chem. 2007 Jan 15;15(2):702-13. Epub 2006 Nov 1.

PMID:
17123821
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.

Vulpetti A, Casale E, Roletto F, Amici R, Villa M, Pevarello P.

J Mol Graph Model. 2006 Mar;24(5):341-8. Epub 2005 Nov 2.

PMID:
16260160
[PubMed - indexed for MEDLINE]
12.

Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.

Waelchli R, Bollbuck B, Bruns C, Buhl T, Eder J, Feifel R, Hersperger R, Janser P, Revesz L, Zerwes HG, Schlapbach A.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):108-12. Epub 2005 Oct 19.

PMID:
16236504
[PubMed - indexed for MEDLINE]
13.

Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.

Griffin RJ, Henderson A, Curtin NJ, Echalier A, Endicott JA, Hardcastle IR, Newell DR, Noble ME, Wang LZ, Golding BT.

J Am Chem Soc. 2006 May 10;128(18):6012-3.

PMID:
16669651
[PubMed - indexed for MEDLINE]
14.

Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.

Davies TG, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, Tucker JA, Wang L, Whitfield HJ.

Nat Struct Biol. 2002 Oct;9(10):745-9.

PMID:
12244298
[PubMed - indexed for MEDLINE]
15.

Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.

Richardson CM, Williamson DS, Parratt MJ, Borgognoni J, Cansfield AD, Dokurno P, Francis GL, Howes R, Moore JD, Murray JB, Robertson A, Surgenor AE, Torrance CJ.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7. Epub 2005 Dec 1.

PMID:
16325401
[PubMed - indexed for MEDLINE]
16.

N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.

Hardcastle IR, Arris CE, Bentley J, Boyle FT, Chen Y, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury P, Menyerol J, Mesguiche V, Newell DR, Noble ME, Pratt DJ, Wang LZ, Whitfield HJ.

J Med Chem. 2004 Jul 15;47(15):3710-22.

PMID:
15239650
[PubMed - indexed for MEDLINE]
17.

Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.

Ashton KS, St Jean DJ Jr, Poon SF, Lee MR, Allen JG, Zhang S, Lofgren JA, Zhang X, Fotsch C, Hungate R.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5191-6. doi: 10.1016/j.bmcl.2011.07.056. Epub 2011 Jul 23.

PMID:
21824779
[PubMed - indexed for MEDLINE]
18.

Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.

Echalier A, Bettayeb K, Ferandin Y, Lozach O, Clément M, Valette A, Liger F, Marquet B, Morris JC, Endicott JA, Joseph B, Meijer L.

J Med Chem. 2008 Feb 28;51(4):737-51. doi: 10.1021/jm700940h. Epub 2008 Jan 31.

PMID:
18232649
[PubMed - indexed for MEDLINE]
19.

Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.

Alam M, Beevers RE, Ceska T, Davenport RJ, Dickson KM, Fortunato M, Gowers L, Haughan AF, James LA, Jones MW, Kinsella N, Lowe C, Meissner JW, Nicolas AL, Perry BG, Phillips DJ, Pitt WR, Platt A, Ratcliffe AJ, Sharpe A, Tait LJ.

Bioorg Med Chem Lett. 2007 Jun 15;17(12):3463-7. Epub 2007 Mar 30.

PMID:
17459703
[PubMed - indexed for MEDLINE]
20.

3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.

Singh SK, Dessalew N, Bharatam PV.

Eur J Med Chem. 2006 Nov;41(11):1310-9. Epub 2006 Aug 4.

PMID:
16890327
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk